Most plastic surgeons will go their entire career without encountering a single case of postsurgical pyoderma gangrenosum (PSPG). But that’s part of the problem.
Despite being rare, PSPG is a high-stakes pitfall with significant aesthetic, functional, and medicolegal consequences. When it appears, especially after breast surgery, it mimics infection or flap necrosis so convincingly that standard treatment protocols often make it worse.
This week, Surgical Aesthetics 411 brings clarity to a murky clinical challenge. Here’s what you need to know to avoid misdiagnosis and protect your patients.
Not Your Typical Post-Op Nightmare
PSPG is an inflammatory neutrophilic dermatosis triggered by surgical trauma. In breast surgery, it’s most frequently seen after reduction mammoplasty but has been reported across various aesthetic and reconstructive procedures, including combined breast-abdominal operations (71.4% of multi-site cases).
What makes PSPG especially dangerous is its deceptive presentation. It looks and behaves like a severe infection or tissue necrosis with rapid ulceration, drainage, and pain. The problem is that it’s not infectious so antibiotics and surgical debridement typically do nothing or even worsen the condition.
The Red Flags You Can’t Ignore
Caddia et al. emphasize four clinical features that should immediately raise suspicion for PSPG:
- Exaggerated pain out of proportion to exam findings (present in 86.2% of cases)
- Nipple–areola complex sparing, even with extensive tissue breakdown (80.7%)
- Very elevated CRP (>200 mg/L), often without leukocytosis
- Negative wound cultures (76.9% of cases) despite clinical signs of “infection”
If you see a wound that’s falling apart despite appropriate antibiotics, pause before escalating to the OR. Early excisional debridement can exacerbate PSPG due to pathergy.
When in Doubt, Stop Cutting and Start Steroids
Systemic corticosteroids remain the first-line treatment. In the reviewed cases, early initiation of immunosuppressive therapy dramatically improved outcomes and shortened healing time (mean: 4.5 months). Surgical reconstruction was still required in nearly 30% of patients, often delayed until the disease was fully controlled.
Other immunomodulators like cyclosporine or biologics (e.g., infliximab) may be considered in refractory cases, though the review focused on corticosteroids as the most consistent therapeutic agent.
The Six Commandments of PSPG
The authors in the study outline six core principles for managing PSPG effectively:
- Suspect it early. The first clue is exaggerated pain and wound deterioration without systemic toxicity.
- Don’t debride blindly. Tissue trauma worsens the condition.
- Order labs wisely. CRP is more informative than WBC; cultures are often negative.
- Start steroids promptly. Delay increases morbidity.
- Coordinate care. Early derm consultation can prevent unnecessary surgeries.
- Counsel patients pre-op. Especially in reduction mammoplasty, include PSPG in informed consent to manage expectations and reduce liability.
Bottom Line
For most surgeons, PSPG will remain rare. But recognizing it quickly can mean the difference between a delayed steroid taper and a long road of complications, reconstruction, and legal risk.
The new research gives you a concrete framework: If a post-op wound is worsening, cultures are negative, CRP is sky-high, and your go-to interventions aren’t working, stop. Don’t escalate. Think PG. Get dermatology on board. Start steroids. Keep this one in the back pocket, and warn your residents. PSPG isn’t common, but when it happens, everyone’s learning curve is steep.
This content is intended for educational purposes only and does not substitute for clinical judgment. Treatment decisions should be based on individual patient needs, professional guidelines, and a comprehensive clinical evaluation.
SOURCES: Aesthetic Surgery Journal
